{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T21:54:35Z","timestamp":1794693275821,"version":"4.9.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["20229ZA2YF"],"award-info":[{"award-number":["20229ZA2YF"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.phrs.2025.107635","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T16:30:48Z","timestamp":1738773048000},"page":"107635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Pharmacological regression of atherosclerotic plaque in patients with type 2 diabetes"],"prefix":"10.1016","volume":"213","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-6529","authenticated-orcid":false,"given":"Loredana","family":"Bucciarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Andreini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-6967","authenticated-orcid":false,"given":"Giulio","family":"Stefanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Maria","family":"Fiorina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Francone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Lunati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1443-5788","authenticated-orcid":false,"given":"Edoardo","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fiorina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.phrs.2025.107635_bib1","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.clinthera.2023.09.020","article-title":"Global trends in atherosclerotic cardiovascular disease","volume":"45","author":"Nedkoff","year":"2023","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2025.107635_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12020432","article-title":"Advances in pharmacological approaches for managing hypercholesterolemia: a comprehensive overview of novel treatments","volume":"12","author":"Mormone","year":"2024","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.phrs.2025.107635_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-2275(20)39898-9","article-title":"Molecular physiology of reverse cholesterol transport","volume":"36","author":"Fielding","year":"1995","journal-title":"J. Lipid Res"},{"issue":"2","key":"10.1016\/j.phrs.2025.107635_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/ncpcardio1086","article-title":"Rapid regression of atherosclerosis: insights from the clinical and experimental literature","volume":"5","author":"Williams","year":"2008","journal-title":"Nat. Clin. Pr. Cardiovasc Med"},{"issue":"6423","key":"10.1016\/j.phrs.2025.107635_bib5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/362801a0","article-title":"The pathogenesis of atherosclerosis: a perspective for the 1990s","volume":"362","author":"Ross","year":"1993","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.phrs.2025.107635_bib6","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.phrs.2025.107635_bib7","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1161\/01.CIR.0000039325.03698.36","article-title":"RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice","volume":"106","author":"Bucciarelli","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.phrs.2025.107635_bib8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2006.02.036","article-title":"Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI","volume":"190","author":"Corti","year":"2007","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.phrs.2025.107635_bib9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3181\/00379727-95-23300","article-title":"Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion","volume":"95","author":"Friedman","year":"1957","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.107635_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1161\/01.RES.27.1.59","article-title":"Regression of coronary atheromatosis in rhesus monkeys","volume":"27","author":"Armstrong","year":"1970","journal-title":"Circ. Res"},{"issue":"11","key":"10.1016\/j.phrs.2025.107635_bib11","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/01.ATV.15.11.1882","article-title":"Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits","volume":"15","author":"Miyazaki","year":"1995","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"9","key":"10.1016\/j.phrs.2025.107635_bib12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/jamacardio.2018.2168","article-title":"Apolipoprotein A-I infusion therapies for coronary disease: two outs in the ninth inning and swinging for the fences","volume":"3","author":"Rader","year":"2018","journal-title":"JAMA Cardiol."},{"issue":"25","key":"10.1016\/j.phrs.2025.107635_bib13","first-page":"30473050","article-title":"High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice","volume":"103","author":"Shah","year":"2001","journal-title":"Potential Implic. Acute Plaque Stab. Circ."},{"issue":"17","key":"10.1016\/j.phrs.2025.107635_bib14","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1161\/01.CIR.100.17.1816","article-title":"Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice","volume":"100","author":"Tangirala","year":"1999","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.phrs.2025.107635_bib15","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1161\/hc4501.098952","article-title":"Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content","volume":"104","author":"Rong","year":"2001","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.phrs.2025.107635_bib16","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00018-002-8491-x","article-title":"RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease","volume":"59","author":"Bucciarelli","year":"2002","journal-title":"Cell Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.phrs.2025.107635_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.atherosclerosis.2005.06.013","article-title":"RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes","volume":"185","author":"Wendt","year":"2006","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.phrs.2025.107635_bib18","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1161\/01.ATV.0000133191.71196.90","article-title":"RAGE axis: animal models and novel insights into the vascular complications of diabetes","volume":"24","author":"Naka","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107635_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s11883-002-0024-4","article-title":"Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes","volume":"4","author":"Wendt","year":"2002","journal-title":"Curr. Atheroscler. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2025.107635_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0092-8674(00)80059-8","article-title":"CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs","volume":"99","author":"Forster","year":"1999","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.phrs.2025.107635_bib21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ni.2205","article-title":"The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques","volume":"13","author":"van Gils","year":"2012","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.phrs.2025.107635_bib22","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.phrs.2025.107635_bib23","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.phrs.2025.107635_bib24","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.0000034508.55617.65","article-title":"ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness","volume":"106","author":"Taylor","year":"2002","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.phrs.2025.107635_bib25","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","article-title":"Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial","volume":"297","author":"Crouse","year":"2007","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.phrs.2025.107635_bib26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3810\/psm.2010.06.1797","article-title":"METEOR trial reports on the effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis","volume":"38","author":"Haddad","year":"2010","journal-title":"Phys. Sport."},{"issue":"4","key":"10.1016\/j.phrs.2025.107635_bib27","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ehjci\/jet251","article-title":"Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN","volume":"15","author":"Puri","year":"2014","journal-title":"Eur. Heart J. Cardiovasc Imaging"},{"issue":"20","key":"10.1016\/j.phrs.2025.107635_bib28","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1097\/CM9.0000000000001067","article-title":"Intensive statin versus low-dose statin + ezetimibe treatment for fibrous cap thickness of coronary vulnerable plaques","volume":"133","author":"Meng","year":"2020","journal-title":"Chin. Med J."},{"issue":"22","key":"10.1016\/j.phrs.2025.107635_bib29","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1161\/CIRCULATIONAHA.113.004243","article-title":"C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy","volume":"128","author":"Puri","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.phrs.2025.107635_bib30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1253\/circj.CJ-11-0730","article-title":"Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study","volume":"76","author":"Kovarnik","year":"2012","journal-title":"Circ. J."},{"issue":"5","key":"10.1016\/j.phrs.2025.107635_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107635_bib32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.carrev.2016.11.010","article-title":"Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial","volume":"18","author":"Hougaard","year":"2017","journal-title":"Cardiovasc Revasc Med."},{"issue":"11","key":"10.1016\/j.phrs.2025.107635_bib33","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1253\/circj.CJ-17-0193","article-title":"Effect of ezetimibe on stabilization and regression of intracoronary plaque - the ZIPANGU study","volume":"81","author":"Ueda","year":"2017","journal-title":"Circ. J."},{"issue":"22","key":"10.1016\/j.phrs.2025.107635_bib34","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"9858","key":"10.1016\/j.phrs.2025.107635_bib35","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebocontrolled, dose-ranging, phase 2 study","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.phrs.2025.107635_bib36","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.phrs.2025.107635_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.21037\/cdt-20-684","article-title":"Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study","volume":"11","author":"Nicholls","year":"2021","journal-title":"Cardiovasc Diagn. Ther."},{"issue":"18","key":"10.1016\/j.phrs.2025.107635_bib38","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"Raber","year":"2022","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.phrs.2025.107635_bib39","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.jacc.2023.08.019","article-title":"Concomitant coronary atheroma regression and stabilization in response to lipid-lowering therapy","volume":"82","author":"Biccire","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"19","key":"10.1016\/j.phrs.2025.107635_bib40","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.122.062557","article-title":"Alirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia: the ARCHITECT study","volume":"147","author":"Perez de Isla","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.phrs.2025.107635_bib41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.mehy.2006.11.026","article-title":"Anti-inflammatory effect is an important property of niacin on atherosclerosis beyond its lipid-altering effects","volume":"69","author":"Yu","year":"2007","journal-title":"Med. Hypotheses"},{"issue":"22","key":"10.1016\/j.phrs.2025.107635_bib42","doi-asserted-by":"crossref","first-page":"15831592","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"40","key":"10.1016\/j.phrs.2025.107635_bib43","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur. Heart J."},{"issue":"24","key":"10.1016\/j.phrs.2025.107635_bib44","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1161\/CIRCULATIONAHA.108.790733","volume":"118","author":"Nicholls","year":"2008","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.phrs.2025.107635_bib45","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2025.107635_bib46","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ahj.2009.07.028","article-title":"Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib","volume":"158","author":"Cannon","year":"2009","journal-title":"Am. Heart J."},{"key":"10.1016\/j.phrs.2025.107635_bib47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.phrs.2017.12.028","article-title":"Present therapeutic role of cholesteryl ester transfer protein inhibitors","volume":"128","author":"Ferri","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107635_bib48","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ahj.2020.10.060","article-title":"Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance","volume":"235","author":"Nicholls","year":"2021","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.phrs.2025.107635_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0297854","article-title":"Safety and efficacy of bempedoic acid among patients with statin intolerance and those without: a meta-analysis and a systematic randomized controlled trial review","volume":"19","author":"Li","year":"2024","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2025.107635_bib50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jacc.2008.03.051","article-title":"Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials","volume":"52","author":"Nicholls","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2025.107635_bib51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1475-2840-11-87","volume":"11","author":"Daida","year":"2012","journal-title":"Cardiovasc Diabetol."},{"issue":"6","key":"10.1016\/j.phrs.2025.107635_bib52","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1253\/circj.CJ-09-0766","volume":"74","author":"Hiro","year":"2010","journal-title":"Circ. J."},{"issue":"9","key":"10.1016\/j.phrs.2025.107635_bib53","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1253\/circj.CJ-11-1303","article-title":"Impact of diabetes mellitus on coronary atherosclerosis and plaque composition under statin therapy - subanalysis of the TRUTH study","volume":"76","author":"Nozue","year":"2012","journal-title":"Circ. J."},{"issue":"41","key":"10.1016\/j.phrs.2025.107635_bib54","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1093\/eurheartj\/eht260","article-title":"Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy","volume":"34","author":"Puri","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2025.107635_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100317","article-title":"HbA1c, Coronary atheroma progression and cardiovascular outcomes","volume":"9","author":"Dykun","year":"2022","journal-title":"Am. J. Prev. Cardiol."},{"issue":"11","key":"10.1016\/j.phrs.2025.107635_bib56","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.2337\/dc14-1121","article-title":"High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN","volume":"37","author":"Stegman","year":"2014","journal-title":"Diabetes Care"},{"issue":"13","key":"10.1016\/j.phrs.2025.107635_bib57","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.phrs.2025.107635_bib58","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2047487312437931","article-title":"Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus","volume":"20","author":"Kataoka","year":"2013","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"12","key":"10.1016\/j.phrs.2025.107635_bib59","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s40618-023-02162-9","article-title":"The antiinflammatory and immunological properties of SGLT-2 inhibitors","volume":"46","author":"Bendotti","year":"2023","journal-title":"J. Endocrinol. Invest"},{"key":"10.1016\/j.phrs.2025.107635_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharm. Res"},{"issue":"3","key":"10.1016\/j.phrs.2025.107635_bib61","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2337\/diabetes.50.3.496","article-title":"Effects of kidney-pancreas transplantation on atherosclerotic risk factors and endothelial function in patients with uremia and type 1 diabetes","volume":"50","author":"Fiorina","year":"2001","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.phrs.2025.107635_bib62","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.atherosclerosis.2013.09.035","article-title":"Coronary and carotid atherosclerosis: how useful is the imaging?","volume":"231","author":"Ibrahimi","year":"2013","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.phrs.2025.107635_bib63","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12933-022-01486-9","article-title":"Liraglutide preserves CD34(+) stem cells from dysfunction Induced by high glucose exposure","volume":"21","author":"Sforza","year":"2022","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.phrs.2025.107635_bib64","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/471823","article-title":"Strategies to reverse endothelial progenitor cell dysfunction in diabetes","volume":"2012","author":"Petrelli","year":"2012","journal-title":"Exp. Diabetes Res."},{"issue":"9","key":"10.1016\/j.phrs.2025.107635_bib65","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.freeradbiomed.2007.06.017","article-title":"Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins","volume":"43","author":"Santilli","year":"2007","journal-title":"Free Radic. Biol. Med."},{"issue":"2","key":"10.1016\/j.phrs.2025.107635_bib66","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.phrs.2025.107635_bib67","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0895-7061(98)00125-3","article-title":"Plasma homocysteine and folate are related to arterial blood pressure in type 2 diabetes mellitus","volume":"11","author":"Fiorina","year":"1998","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2025.107635_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.876795","article-title":"Glucose-lowering and the risk of cardiovascular events with antidiabetic therapies: a systematic review and additive-effects network metaanalysis","volume":"9","author":"de Carvalho","year":"2022","journal-title":"Front. Cardiovasc Med."},{"issue":"24","key":"10.1016\/j.phrs.2025.107635_bib69","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1016\/j.jacc.2010.01.050","article-title":"Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol","volume":"55","author":"Bayturan","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.phrs.2025.107635_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094906","article-title":"The anti-atherosclerosis effect of Anakinra, a recombinant human interleukin-1 receptor antagonist, in apolipoprotein E knockout mice","volume":"23","author":"Ku","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.phrs.2025.107635_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1206","article-title":"Inhibition of interleukin-1beta signalling promotes atherosclerotic lesion remodelling in mice with inflammatory arthritis","volume":"9","author":"Dragoljevic","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"8","key":"10.1016\/j.phrs.2025.107635_bib72","first-page":"34903503","article-title":"P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes","volume":"128","author":"D'Addio","year":"2018","journal-title":"J. Clin. Invest"},{"issue":"5","key":"10.1016\/j.phrs.2025.107635_bib73","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3892\/ijmm.2015.2129","article-title":"P2X7R is involved in the progression of atherosclerosis by promoting NLRP3 inflammasome activation","volume":"35","author":"Peng","year":"2015","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.107635_bib74","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.atherosclerosis.2013.01.024","article-title":"The role of ADAM17 in metabolic inflammation","volume":"228","author":"Menghini","year":"2013","journal-title":"Atherosclerosis"},{"issue":"24","key":"10.1016\/j.phrs.2025.107635_bib75","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.phrs.2025.107635_bib76","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cmet.2024.05.001","article-title":"Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule","volume":"36","author":"Ben Nasr","year":"2024","journal-title":"Cell Metab."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182500060X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182500060X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T12:25:32Z","timestamp":1745583932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366182500060X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":76,"alternative-id":["S104366182500060X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107635","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological regression of atherosclerotic plaque in patients with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107635"}}